All Stories
Follow
Subscribe to Medigene AG

Medigene AG

ots Ad hoc-Service: MediGene AG <DE0005020903> MEDIGENE RECEIVES EUROPEAN MARKETING RIGHTS FOR LATE STAGE PROSTATE CANCER DRUG LEUPROGEL(TM)

Martinsried (ots Ad hoc-Service) -

Ad hoc-announcement. The sender is solely
responsible for the contents of this announcement.
MEDIGENE RECEIVES EUROPEAN
MARKETING RIGHTS FOR LATE STAGE PROSTATE CANCER DRUG LEUPROGEL(TM)
Agreement pushes MediGene closer to commercialization of first
drug
The international biopharmaceutical company MediGene AG (NMarkt:
MDG) announced today that it has entered into an exclusive European
marketing agreement with Atrix Laboratories, Inc. for three products
based on Leuprogel(TM) to treat advanced prostate cancer. Atrix
Laboratories, Inc. (Nasdaq NM: ATRX) is an emerging specialty
pharmaceutical company focused on advanced drug delivery. The
clinical trials for the Leuprogel(TM) One Month product have been
successfully completed with encouraging results and a new drug
application (NDA) has been submitted to the FDA. The phase 3 trials
for the three-month and four-month application of Leuprogel(TM) are
in progress and Atrix expects to submit an NDA for the Leuprogel
Three-Month product later this year (for additional information on
Leuprogel(TM) and the clinical trials please refer to the Atrix
Laboratories, Inc. Web site at http://www.atrixlabs.com).
Under the terms of the agreement, MediGene will provide all
resources needed to conduct clinical research and regulatory
activities associated with seeking European marketing approvals. The
agreement includes an option for MediGene to develop and market
Leuprogel(TM) for additional indications. Atrix will receive license
fees and payments for certain clinical, regulatory and sales
milestones which could amount to approximately US$ 20 million
including the purchase of US$ 4 million in shares of Atrix's common
stock. In addition, Atrix will receive royalty payments based on
MediGene's sales of the Leuprogel products and will manufacture
Leuprogel for MediGene.
For further information please contact:
MediGene AG email:  investor@medigene.de fax: ++49 - 89 - 89 56
32-20
Christine Bohner, Public Relations phone: ++49 - 89 - 89 56 32-16
Michael Nettersheim, Investor Relations phone: ++49 - 89 - 89 56
32-46
WKN: 502090; Index: NEMAX- 50 Listed: Neuer Markt in Frankfurt;
Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München
und Stuttgart
End
Internet: http://recherche.newsaktuell.de

Original content of: Medigene AG, transmitted by news aktuell

More stories: Medigene AG
More stories: Medigene AG